<DOC>
	<DOCNO>NCT00939991</DOCNO>
	<brief_summary>This Phase I/II open-label , single-arm study among recurrent malignant glioma patient . Patients treat Vorinostat combination Bevacizumab ( BV ) ( 10 mg/kg ) Temozolomide ( T ) ( 50 mg/m2/day ) BV administer every 2 week . Temozolomide take orally every day . Vorinostat take orally day 1-7 15-21 28-day cycle . In phase I portion study , dose Vorinostat escalate successive cohort patient determine maximum tolerate dose ( MTD ) base dose-limiting toxicity ( DLTs ) . In phase II portion study , dose Vorinostat MTD determine phase I portion . The primary endpoint phase II study 6-month progression-free survival ( PFS ) recurrent GBM ( Glioblastoma ) patient . This study conduct The Preston Robert Tisch Brain Tumor Center Duke .</brief_summary>
	<brief_title>Suberoylanilide Hydroxamic Acid ( SAHA ) , Bevacizumab , Daily Temozolomide Recurrent Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Patients must histologically confirm diagnosis malignant glioma radiographic evidence recurrence disease progression ( define either great 25 % increase large bidimensional product enhancement new enhance lesion ) follow prior therapy . In addition , follow must meet : Phase I specific WHO grade 3 4 malignant glioma Phase II specific WHO grade 4 malignant glioma No 2 prior episodes disease progression Common Phase I Phase II Age * 18 year KPS ( Karnofsky Performance Scale ) ≥ 70 % An interval least 4 week prior surgical resection one week stereotactic biopsy An interval least 12 week end prior radiotherapy unless new area enhancement consistent recurrent tumor outside radiation field , progressive change MRI least two consecutive MRI scan least four week apart , biopsyproven tumor progression An interval least 4 week prior chemotherapy ( 6 week nitrosoureas ) investigational agent unless patient recover anticipated toxicity associate therapy Hematocrit ≥ 29 % , ANC ≥ 1,000 cells/*l , platelet ≥ 100,000 cells/*l Serum creatinine &lt; 1.5 time upper limit normal , serum SGOT &lt; 2.5 time upper limit normal bilirubin &lt; 2.0 time upper limit normal Signed inform consent approve Institutional Review Board prior patient entry No evidence hemorrhage baseline MRI CT scan stable grade 1 If sexually active , patient take contraceptive measure duration treatment . Medically acceptable contraceptive include : 1. surgical sterilization ( tubal ligation , hysterectomy , vasectomy ) , 2. approve hormonal contraceptive ( birth control pill , patch , implant injection ) , 3. barrier method ( condom diaphragm ) use spermicide , 4. intrauterine device ( IUD ) . Prior therapy histone deacetylase inhibitor ; valproic acid permit patient previously treat valproic acid must valproic acid least 30 day prior initiation study medication Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid Active infection require intravenous antibiotic Progression prior bevacizumab daily temozolomide Grade 3 great toxicity relate prior bevacizumab daily temozolomide therapy Requires therapeutic anticoagulation warfarin Life expectancy &lt; 12 week Active malignancy basal squamous cell skin ca carcinoma situ cervix within 5 year Subject recruitment compensation subject recruit study follow : Upon determination subject 's tumor histology and/or radiographic finding compatible eligibility criterion protocol , clinical study briefly explain subject subject 's physician , physician Brain Tumor Center Duke . If subject indicate interest study participation , subject education sheet informed consent document provide subject provide comprehensive explanation study lay term . If subject show continue interest , PI designee thoroughly explain required element consent form aspect study subject include inclusion/exclusion criterion , risk , benefit , alternative study participation . Subjects pay take part research study . The list subject prescreened kept Excel spreadsheet study coordinator 's office . The PC ( personal computer ) DUHS ( Duke University Health System ) network protect user ID ( identifier ) password office lock unoccupied . All screened subject enrol study identifier destroy immediately .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>GBM</keyword>
</DOC>